Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
READIT: TKI Dose Reduction and Discontinuation in CML
NCT04578847Phase 2Unknown
- Sponsor
- National Medical Research Center for Hematology
- Start
- Jan 2020
- Primary completion
- Jan 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of imatinib, nilotinib, dasatinib and bosutinib in chronic myeloid leukemia (CML), sponsored by National Medical Research Center for Hematology. Primary endpoint: Overall Survival at 37 months. Status: unknown.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04578847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04578847.